White House Denies Trump’s Access to Eli Lilly Obesity Drug via Compassionate Use
White House bats down speculation that – On Tuesday, White House officials dismissed claims that President Donald Trump had received access to the retatrutide obesity drug through the Food and Drug Administration’s (FDA) compassionate use program. The assertion, which emerged from a report published by STAT News, suggested that the drug might have been approved for a patient in Trump’s age group, sparking speculation about his personal use of the medication. Officials emphasized that the program, designed to provide experimental treatments to patients with severe illnesses, was not intended for the president.
The Controversy Over Retatrutide
Retatrutide, developed by Eli Lilly, is a weight-loss drug currently under investigation but not yet FDA approved. It is part of a broader class of medications targeting obesity, with potential applications for conditions like diabetes and metabolic disorders. However, its use in the compassionate use program raises questions about eligibility criteria and the broader implications of such access for high-profile individuals.
According to anonymous sources with knowledge of the situation, the patient approved for retatrutide was 79 years old. This detail, combined with Trump’s recent birthday—turning 80 last week—led STAT News to speculate that the prescription might have been issued to him. The article noted that the patient’s condition, refractory obesity, is characterized by an inability to achieve and maintain a 5% weight loss over six months, even with intensive therapies.
White House’s Defiant Response
In a post on X, White House senior deputy press secretary Kush Desai directly addressed the speculation, targeting reporter Lizzy Lawrence, who had authored the article. “Because this has to be spelled out for @LizzyLaw, who has proven herself to be an unserious gossip columnist, this application was not for the President,” Desai wrote. The comment implies that the report was overreaching, with the press secretary suggesting Lawrence’s work lacked journalistic rigor.
Desai’s response also criticized Lawrence for not seeking clarification from the broader population of patients in the same age cohort. “Are you going to now go ask this idiotic question to the ~4 million Americans in this age group and then speculate about them being the application?” he added, highlighting the perceived bias in the reporting. This exchange underscored the tension between the administration and media outlets, with the White House framing the issue as a matter of credibility.
Lawrence, in turn, pointed out that the White House and Department of Health and Human Services had not responded to her inquiries about whether Trump was using the obesity drug. “We shouldn’t have to bat down baseless speculation for you to not print it. Any reporter with standards would understand this,” Desai replied in a follow-up, challenging the validity of the report and questioning Lawrence’s approach to fact-checking.
Trump’s Health and Public Scrutiny
While the White House denies Trump’s personal use of retatrutide, the president has openly discussed his weight and health concerns in recent months. According to a physical examination conducted last year, Trump weighs 224 pounds, a figure he has previously mentioned as a reason for considering weight loss medications. In an interview with The New York Times, he acknowledged that “probably” he should be on such drugs, though he stopped short of confirming he had been prescribed them.
His comments have drawn attention to broader questions about his health management, particularly after reports of fatigue during Cabinet meetings and other public appearances. Some critics have noted his tendency to close his eyes briefly, raising concerns about his vitality and energy levels. This pattern has been contrasted with the medical condition of the retatrutide patient, who was diagnosed with obstructive sleep apnea and pulmonary hypertension, as stated in the request submitted by Ranganath Muniyappa, a senior clinician at the National Institutes of Health.
The connection between Trump’s weight and the drug’s use has fueled ongoing debates about the administration’s transparency. While the White House insists the compassionate use program was not applied to him, the timing of the report—just days after his 80th birthday—has heightened scrutiny. Analysts suggest that the patient’s age, coupled with Trump’s public discussions about his health, created a narrative ripe for interpretation.
The Compassionate Use Program Explained
The FDA’s compassionate use program, also known as expanded access, allows patients to receive unapproved drugs when standard treatments fail. This process is typically reserved for those with life-threatening conditions, such as cancer or rare neurological disorders, where the potential benefits outweigh the risks. Retatrutide’s inclusion in the program reflects its experimental status and the urgency of treating severe obesity cases.
However, the program’s flexibility has sparked discussions about its application to individuals outside the typical patient profile. The approval of retatrutide for a 79-year-old patient, while medically justified, raises questions about whether such access is being used to address broader public health concerns. Critics argue that high-profile figures like Trump may benefit from the program’s leniency, using it as a platform to discuss their health in the media.
Experts emphasize that the compassionate use program is a critical tool for patients with no other options, but its use for Trump has been seen as a strategic move. “The president’s weight has been a topic of discussion for years, and this could be another way to bring attention to it,” said one medical analyst. “It’s not just about the drug—it’s about the narrative surrounding his health and fitness.”
White House Communications Director’s Jab
Steven Cheung, the White House Communications Director, further criticized Lawrence in a separate post on X, calling her “a big idiot” for prioritizing clicks over accuracy. “You thought this was your big shot, but in reality, you’re just a big idiot. You certainly made a name for yourself by completely embarrassing yourself at the expense of being thirsty for clicks and peddling falsehoods,” he wrote. This public rebuke reflected the administration’s frustration with media outlets it perceives as sensationalizing information.
The exchange highlights a growing divide between the White House and the press, with officials accusing journalists of relying on speculation rather than verified facts. Desai’s and Cheung’s comments suggest a desire to control the narrative around the drug’s use, positioning it as a distraction from more pressing issues. Meanwhile, Lawrence’s report has reignited conversations about the role of media in shaping public perception of the president’s health.
Public Reaction and Broader Implications
Public reaction to the report has been mixed, with some supporting the White House’s defense of the program and others questioning its exclusivity. Social media discussions have focused on the potential benefits of retatrutide for weight management, while others have highlighted the political undertones of the situation. “It’s a small step for the FDA, but a giant leap for the administration’s image,” remarked a health policy expert.
As the debate continues, the focus remains on the balance between medical innovation and public accountability. The compassionate use program, while essential for patients in need, has become a battleground for narratives about the president’s health. Whether or not Trump personally used retatrutide, the incident has underscored the importance of transparency in high-profile medical cases.
